+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Plasma Levels of Endothelin-1 in Retinitis Pigmentosa

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Retinitis pigmentosa (RP) is an inherited retinal disorder clinically characterized by a pale, waxy optic nerve head, attenuated retinal blood vessels and bone spicule pigment in the retina. Hemodynamic studies have demonstrated that RP is associated with a reduction in the retinal and choroidal blood flow. Retinal hemodynamic impairment is also present in the early stages of RP and various hypotheses have been advanced as to its cause. The authors studied 20 patients, 12 males and 8 females, aged between 26 and 42 years (mean 34.6 years) affected by simplex RP. The twenty patients were divided in two groups according to the degree of sight impairment: group A consisted of 10 patients with a visual acuity of 0.3 ± 0.1, visual field mean defect 18.988 ± 3.419 dB and b-wave electroretinogram amplitude of 13.14 ± 0.308 µV. Group B consisted of 10 patients with a visual acuity of 0.8 ± 0.2, visual field MD 10.523 ± 3.582 dB and b-wave electroretinogram amplitude of 26.000 ± 0.757 µV. An increase in plasma levels of endothelin-1 (ET-1) was found as compared with healthy controls: 1.910 ± 0.617 pg/ml vs. 1.180 ± 0.210 pg/ml (p < 0.021), but there was no statistical difference between group A and B (p < 0.163). It is thought that an increase in ET-1 and retinal oxygen levels in RP could lead to vasoconstriction and a decrease in the retinal blood flow worsening the abiotrophic process.

          Related collections

          Most cited references 1

          • Record: found
          • Abstract: not found
          • Article: not found

          Endothelin 1 is a Growth Factor for Corneal Endothelium


            Author and article information

            S. Karger AG
            August 2002
            29 August 2002
            : 216
            : 4
            : 265-268
            University of Bologna, Institute of Ophthalmology, Bologna, Italy
            63841 Ophthalmologica 2002;216:265–268
            © 2002 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            Page count
            Figures: 1, Tables: 2, References: 27, Pages: 4
            Original Paper · Travail original · Originalarbeit


            Comment on this article